SOPH SOPHiA GENETICS, Inc.
$7.87
SOPHiA GENETICS, Inc. (SOPH) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Insider signal
Bearish
Selling ran elevated versus SOPH's own trailing one-year pace, with 100% of sale value under a prearranged plan.
Cluster activity
0 buyers in the last 30 days
0 buyers in the last 90 days
9 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
9
52 transactions
Purchases
$0
0 shares
Sales
$3.0M
460,271 shares
Net activity
-$3.0M
purchases less sales
How much of that selling was preplanned? 100% planned / 0% discretionary
10b5-1 plan sales
$3.0M
49 transactions · 460,055 shares
Discretionary sales
$1.1K
3 transactions · 216 shares
Largest single sale: $279.0K.
Where they traded
Buy
Sell
Dot area is proportional to transaction value.
Last open-market purchase: June 5, 2026 , by CARDOZA GEORGE .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| HIBBS KATHY L | Director | Sell 10b5-1 | 6,250 | $8.13 | $50.8K | 96,992 −6.1% of holding | |
| Xu Zhenyu | Chief Scientific Officer | Sell 10b5-1 | 10,000 | $8.91 | $89.1K | 556,887 −1.8% of holding | |
| HIBBS KATHY L | Director | Sell 10b5-1 | 6,250 | $8.68 | $54.2K | 103,242 −5.7% of holding | |
| Menu Philippe | Chief Medical Officer | Sell 10b5-1 | 5,000 | $8.68 | $43.4K | 213,387 −2.3% of holding | |
| Verma Abhimanyu | Chief Technology Officer | Sell 10b5-1 | 5,000 | $8.80 | $44.0K | 172,171 −2.8% of holding | |
| Xu Zhenyu | Chief Scientific Officer | Sell 10b5-1 | 5,408 | $8.40 | $45.4K | 566,887 −0.9% of holding | |
| Xu Zhenyu | Chief Scientific Officer | Sell 10b5-1 | 4,592 | $8.41 | $38.6K | 572,295 −0.8% of holding | |
| Valente Manuela | Chief People Officer | Sell 10b5-1 | 10,000 | $7.94 | $79.4K | 210,450 −4.5% of holding | |
| Xu Zhenyu | Chief Scientific Officer | Sell 10b5-1 | 10,000 | $7.94 | $79.4K | 576,887 −1.7% of holding | |
| Verma Abhimanyu | Chief Technology Officer | Sell 10b5-1 | 5,000 | $8.20 | $41.0K | 177,171 −2.7% of holding | |
| Xu Zhenyu | Chief Scientific Officer | Sell 10b5-1 | 4,000 | $7.52 | $30.1K | 586,887 −0.7% of holding | |
| Menu Philippe | Chief Medical Officer | Sell 10b5-1 | 5,000 | $7.52 | $37.6K | 218,387 −2.2% of holding | |
| Camblong Jurgi | Executive Chairman | Sell 10b5-1 | 8,500 | $7.61 | $64.7K | 3,444,322 −0.2% of holding | |
| Camblong Jurgi | Executive Chairman | Sell 10b5-1 | 20,000 | $7.23 | $144.5K | 3,452,822 −0.6% of holding | |
| Xu Zhenyu 2 fills | Chief Scientific Officer | Sell 10b5-1 | 17,000 | $7.29 | $123.9K | 600,887 −2.8% of holding | |
| Verma Abhimanyu | Chief Technology Officer | Sell 10b5-1 | 5,000 | $7.60 | $38.0K | 182,171 −2.7% of holding | |
| Xu Zhenyu | Chief Scientific Officer | Sell 10b5-1 | 3,000 | $7.00 | $21.0K | 600,887 −0.5% of holding | |
| Camblong Jurgi | Executive Chairman | Sell 10b5-1 | 20,000 | $6.92 | $138.4K | 3,472,822 −0.6% of holding | |
| Xu Zhenyu | Chief Scientific Officer | Sell 10b5-1 | 10,000 | $6.92 | $69.2K | 600,887 −1.6% of holding | |
| Verma Abhimanyu | Chief Technology Officer | Sell 10b5-1 | 5,000 | $6.95 | $34.8K | 187,171 −2.6% of holding | |
| Menu Philippe | Chief Medical Officer | Sell 10b5-1 | 5,000 | $5.66 | $28.3K | 223,387 −2.2% of holding | |
| Camblong Jurgi | Executive Chairman | Sell 10b5-1 | 20,000 | $6.63 | $132.7K | 3,492,822 −0.6% of holding | |
| Camblong Jurgi 2 fills | Executive Chairman | Sell 10b5-1 | 24,381 | $6.29 | $153.4K | 3,512,822 −0.7% of holding | |
| Menu Philippe | Chief Medical Officer | Sell 10b5-1 | 5,000 | $5.70 | $28.5K | 228,387 −2.1% of holding | |
| Xu Zhenyu | Chief Scientific Officer | Sell 10b5-1 | 4,000 | $5.70 | $22.8K | 610,887 −0.7% of holding | |
| Camblong Jurgi | Executive Chairman | Sell 10b5-1 | 8,500 | $5.62 | $47.8K | 3,532,622 −0.2% of holding | |
| Camblong Jurgi | Executive Chairman | Sell 10b5-1 | 17,685 | $5.28 | $93.3K | 3,541,122 −0.5% of holding | |
| Camblong Jurgi | Executive Chairman | Sell 10b5-1 | 22,486 | $5.25 | $118.2K | 3,558,807 −0.6% of holding | |
| Muken Ross | Chief Executive Officer | Sell 10b5-1 | 9,838 | $5.22 | $51.4K | 670,651 −1.4% of holding | |
| Xu Zhenyu | Chief Scientific Officer | Sell 10b5-1 | 7,393 | $5.17 | $38.2K | 614,887 −1.2% of holding | |
| Menu Philippe | Chief Medical Officer | Sell 10b5-1 | 7,393 | $5.16 | $38.2K | 233,387 −3.1% of holding | |
| Verma Abhimanyu | Chief Technology Officer | Sell 10b5-1 | 5,285 | $5.10 | $27.0K | 192,171 −2.7% of holding | |
| Valente Manuela | Chief People Officer | Sell 10b5-1 | 4,241 | $5.05 | $21.4K | 210,450 −2% of holding | |
| CARDOZA GEORGE | Chief Financial Officer | Sell 10b5-1 | 1,592 | $5.29 | $8.4K | 309,092 −0.5% of holding | |
| Puylaert Kevin 3 fills | Chief Sales Officer | Sell | 216 | $5.03 | $1.1K | 148,026 −0.1% of holding | |
| Camblong Jurgi 3 fills | Executive Chairman | Sell 10b5-1 | 65,269 | $6.11 | $398.6K | 3,601,143 −1.8% of holding | |
| Camblong Jurgi 2 fills | Executive Chairman | Sell 10b5-1 | 18,410 | $5.87 | $108.1K | 3,601,493 −0.5% of holding | |
| Camblong Jurgi 2 fills | Chief Executive Officer | Sell 10b5-1 | 50,069 | $5.80 | $290.3K | 3,601,493 −1.4% of holding | |
| Verma Abhimanyu | Chief Technology Officer | Sell 10b5-1 | 6,944 | $5.51 | $38.2K | 197,456 −3.4% of holding | |
| Menu Philippe | Chief Medical Officer | Sell 10b5-1 | 5,000 | $5.50 | $27.5K | 240,780 −2% of holding | |
| Camblong Jurgi | Chief Executive Officer | Sell 10b5-1 | 1,373 | $5.70 | $7.8K | 3,619,622 −0% of holding | |
| CARDOZA GEORGE | Chief Financial Officer | Sell 10b5-1 | 774 | $5.38 | $4.2K | 310,684 −0.2% of holding | |
| Muken Ross | President | Sell 10b5-1 | 422 | $5.38 | $2.3K | 680,489 −0.1% of holding | |
| Xu Zhenyu | Chief Scientific Officer | Sell 10b5-1 | 4,000 | $5.01 | $20.1K | 622,280 −0.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.